Sweden
· Delayed Price · Currency is SEK IRLAB Therapeutics AB Company Description
IRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson’s disease.
The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; and Pirepemat, which is in phase IIb clinical trial for the treatment of Postural dysfunction.
Its preclinical stage products include IRL942 research programs for the treatment of neurodegenerative disorders and ageing; IRL1117, a drug candidate developed for once-daily oral treatment for the hallmark symptoms of Parkinson’s; and IRL757 to treat apathy in neurological diseases.
In addition, the company develops P003, a research project that develops drugs for the treatment of newly diagnosed Parkinson’s disease.
IRLAB Therapeutics AB (publ) was incorporated in 2013 and is headquartered in Gothenburg, Sweden.
| Country | Sweden |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 34 |
| CEO | Kristina Torfgard |
Contact Details
Address: Arvid Wallgrens Backe 20 Gothenburg, 413 46 Sweden | |
| Phone | 46 3 17 57 38 00 |
| Website | irlab.se |
Stock Details
| Ticker Symbol | IRLAB.A |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0012675361 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Kristina Torfgard Ph.D. | Chief Executive Officer |
| Viktor Siewertz | Chief Financial Officer |
| Dr. Clas Sonesson Ph.D. | Chief Scientific Officer |
| Dr. Peder Svensson Ph.D. | Chief Information Officer and Director of Computational Chemistry and Biology |
| Tove Bergenholt | Global IR and Communications |
| Cecilia Tivert Stenberg B.Sc, B.Sc. | Head of Finance and Human Resource and Director of Accounting & Human Resources |
| Dr. Nicholas Waters Ph.D. | Executive Vice President and Head of Research & Development |
| Dr. Joakim Tedroff M.D., Ph.D. | Chief Medical Officer |